Prognostic factor analysis of preoperative radiotherapy for esophageal squamous cell carcinoma
WANG Qi-feng, ZHANG Wen-cheng,XIAO Ze-fen, ZHANG Hong-xing, CHEN Dong-fu,FENG Qin-fu, ZHOU Zong-mei, Lv Ji-ma, LIANG Jun, WANG Lü-hua, YIN Wei-bo
Department of Radiation Oncology, Cancer Hospital (Institute), Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021, China Corresponding author:XIAO Ze-fen,Email:xiaozefen@sina.com
Abstract：Objective To evaluate the prognostic factors affecting preoperative radiotherapy for esophageal squamous cell carcinoma (ESCC). Methods Three hundred and eleven patients with ESCC undergone preoperative radiotherapy were retrospectively analyzed. Detailed clinical and histological materials and radiotherapy and surgery records were examined. Univariate and multivariate analyses were used to study the factors affecting prognosis. Results The follow-up rate was 96.5%, 123 and 86 patients,respectively were followed up more than 3 and 5years. The 5-year survival rates of patients without (106 patients) and with (205 patients) tumorremnants in primary locations after radiotherapy were 43.2% and 23.2%, respectively (χ2=11.53,P=0.001). The 5-year survival rates of 129 patients with primary tumor remnants but without lymph node metastasis in the T1+T2 phase, the T3 phase and the T4 phase were 42%, 30% and 16%, respectively (χ2=20.20,P=0.000). The 5-year survival rates of patients without lymph node metastasis (211 patients) and those whose lymph node metastases numbered less than 4(95 patients) was 38.3% and 13%, respectively;the 3-year survival rate of patients whose lymph node metastases numbered greater than 4 was 14%, and the 5-year survival rate was 0(χ2=42.13,P=0.000). In multivariate analysis, the local region with or without residual cancer, the depth of tumor infiltration, the status of the lymph node, the number of lymph node metastases, and gender were independent prognostic factors (χ2=32.20,36.33,18.24,4.60,6.21, P=0.000, 0.000, 0.000, 0.032, 0.013, respectively). Conclusions Histological T and N staging following preoperative radiotherapy for ESCC andnumbers oflymph node metastases were critical factors affecting prognosis and could be used for better prediction.
. Prognostic factor analysis of preoperative radiotherapy for esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2012, 21(2): 131-135.
[1] Huang GJ, Gu XZ, Zhang RG, et al. Combined preoperative irradiation and surgery in esophageal carcinoma. Report of 408 cases. Chin Med J,1981,94:73-76. [2] Wang M, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma:report on 206 patients. Int J Radiat Oncol Biol Phys, 1989,16:325-327. [3] Wang M, Gu XZ, Yin WB, et al. Randomized trial on combined preoperative irradiation and surgery in the treatment of esophageal carcinoma:report on 418 patients. Chin J Radiat Oncol,2001,10:168-172. [4] 欧广飞,汪楣,王绿化,等,食管癌术前放疗后病理反应与预后的关系,中华肿瘤杂志,2003,25:278-281. [5] Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med,1996,335:462-467. [6] Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med,1997,337:161-167. [7] Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol,2001,19:305-313. [8] Heath EI, Burtness BA, Heitmiller RF, et al. Phase Ⅱ evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol, 2000,18:868-876. [9] Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer:final results of a minnie pearl cancer research network phase Ⅱ trial. Cancer J,2003,9:251-260. [10] Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus:final report. J Clin Oncol,1993,11:1118-1123. [11] Kleinberg L, Knisely JP, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44 Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys,2003,56:328-334. [12] Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol,2005,23:4330-4337. [13] Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol,2007,25:507-512. [14] Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer,2005,103:1347-1355. [15] Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer,1994,73:1779-1784. [16] Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology,1994,41:391-393. [17] Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma:a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg,1992,16:1104-1110. [18] Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia:a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg,1997,113:836-846. [19] Xiao ZF, Yang ZY, Miao YJ, et al. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy:report of 549 cases. Int J Radiat Oncol Biol Phys,2005,62:82-90. [20] Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the US:the importance of tumor length and lymph node status. Cancer,2002,95:1434-1443. [21] Tachibana M, Kinugasa S, Dhar DK, et al. Prognostic factors after extended esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Surg Oncol,1999,72:88-93. [22] Kimura H, Konishi K, Arakawa H, et al. Number of lymph node metastases influences survival in patients with thoracic esophageal carcinoma:therapeutic value of radiation treatment for recurrence. Dis Esophagus,1999,12:205-208. [23] Hsu CP, Chen CY, Hsia JY, et al. Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus. Eur J Cardiothorac Surg,2001,19:10-13. [24] Kawahara K, Maekawa T, Okabayashi K, et al. The number of lymph node metastases influences survival in esophageal cancer. J Surg Oncol,1998,67:160-163.
2012, Vol. 21 
